VRDN

Viridian Therapeutics Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 2/10
  • Value↓ 0/10
Viridian Therapeutics sales and earnings growth
VRDN Growth
Fair
  • Revenue Y/Y↑ 23359.93%
  • EPS Y/Y↓ -8.14%
  • FCF Y/Y↓ -18.92%
Viridian Therapeutics gross and profit margin trends
VRDN Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -483.60%
  • ROIC 5Y↓ -69.43%
Viridian Therapeutics net debt vs free cash flow
VRDN Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -68.2

Viridian Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗